MCID: LRY018
MIFTS: 44

Laryngeal Squamous Cell Carcinoma

Categories: Cancer diseases, Oral diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Laryngeal Squamous Cell Carcinoma

MalaCards integrated aliases for Laryngeal Squamous Cell Carcinoma:

Name: Laryngeal Squamous Cell Carcinoma 12 55 15 17
Epidermoid Carcinoma of the Larynx 12
Squamous Cell Carcinoma of Larynx 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2876
NCIt 50 C4044
UMLS 72 C0280324

Summaries for Laryngeal Squamous Cell Carcinoma

Disease Ontology : 12 A laryngeal carcinoma that has material basis in squamous cells.

MalaCards based summary : Laryngeal Squamous Cell Carcinoma, also known as epidermoid carcinoma of the larynx, is related to larynx cancer and squamous cell papilloma. An important gene associated with Laryngeal Squamous Cell Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Cetuximab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lymph node, thyroid and endothelial, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Laryngeal Squamous Cell Carcinoma

Diseases related to Laryngeal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 226)
# Related Disease Score Top Affiliating Genes
1 larynx cancer 32.9 TP53 TERT NME1 MIR21 EGFR CDKN2A
2 squamous cell papilloma 31.9 TP53 CDKN2A AURKA
3 in situ carcinoma 31.2 TP53 EGFR CDKN2A CDH1
4 verrucous carcinoma 31.0 TP53 CDKN2A CCND1
5 recurrent respiratory papillomatosis 31.0 TP53 EGFR
6 oropharynx cancer 30.9 TP53 EGFR CDKN2A CDH1 CCND1
7 familial adenomatous polyposis 30.8 TP53 CDH1 CCND1
8 oral cavity cancer 30.7 TP53 EGFR CDH1
9 intrahepatic cholangiocarcinoma 30.5 TP53 EGFR CDH1 CCAT1
10 laryngeal disease 30.2 TP53 NME1 EGFR CDKN2A CDH1 CCND1
11 retinoblastoma 30.1 TP53 MALAT1 HOTAIR CDKN2A CCND1 CCAT1
12 squamous cell carcinoma, head and neck 30.1 TP53 MIR21 HOTAIR H19 EGFR CDKN2A
13 thyroid cancer, nonmedullary, 1 30.0 NEAT1 MALAT1 HOTAIR H19
14 adenocarcinoma 29.7 TP53 MALAT1 H19 EGFR CDKN2A CDH1
15 squamous cell carcinoma 29.7 TP53 NME1 NEAT1 MALAT1 HOTAIR H19
16 lung cancer susceptibility 3 28.6 TP53 TERT MALAT1 HOTAIR H19 EGFR
17 cholangiocarcinoma 28.2 TP53 TERT NEAT1 MIR21 MALAT1 H19
18 bladder cancer 28.0 TP53 TERT MIR21 MALAT1 HOTAIR H19
19 pancreatic cancer 27.1 TP53 NEAT1 MIR21 MALAT1 HOTAIR H19
20 nasopharyngeal carcinoma 26.9 TP53 TERT NME1 NEAT1 MALAT1 HOTAIR
21 cervical cancer 25.8 TP53 TERT NME1 NEAT1 MIR21 MALAT1
22 colorectal cancer 25.7 TP53 TERT NME1 NEAT1 MIR21 MALAT1
23 breast papillomatosis 10.8 CDKN2A CCND1
24 brain ependymoma 10.8 TP53 EGFR
25 tonsil squamous cell carcinoma 10.8 CDKN2A CCND1
26 cerebral convexity meningioma 10.7 TP53 CDH1
27 male reproductive system disease 10.7 TP53 CDH1 CCND1
28 oral leukoplakia 10.7 TP53 CDKN2A CCND1
29 bladder squamous cell carcinoma 10.7 TP53 CDKN2A
30 malignant peritoneal mesothelioma 10.7 EGFR CDKN2A
31 inverted papilloma 10.7 TP53 CDKN2A CCND1
32 retinal cancer 10.7 TP53 CDKN2A CCND1
33 hidradenocarcinoma 10.7 TP53 EGFR CCND1
34 basaloid squamous cell carcinoma 10.7 TP53 EGFR CDKN2A
35 tongue disease 10.7 TP53 CDKN2A CDH1
36 vulva cancer 10.7 TP53 EGFR CDKN2A
37 bowenoid papulosis 10.7 TERT CDKN2A CCND1
38 keratinizing squamous cell carcinoma 10.7 TP53 CDKN2A
39 tonsil cancer 10.7 TP53 CDKN2A CDH1
40 ocular cancer 10.7 TP53 CDKN2A CCND1
41 estrogen-receptor positive breast cancer 10.7 TP53 EGFR CCND1
42 spitz nevus 10.7 TP53 CDKN2A
43 papilloma 10.6
44 cholecystitis 10.6 TP53 CDKN2A CDH1
45 small cell carcinoma 10.6 TP53 EGFR CDKN2A
46 anaplastic oligodendroglioma 10.6 EGFR CDKN2A
47 cervical squamous cell carcinoma 10.6 TP53 CDKN2A CDH1
48 skin carcinoma in situ 10.6 CDKN2A CCND1
49 obsolete: squamous cell carcinoma of head and neck 10.6
50 soft tissue sarcoma 10.6 TP53 TERT EGFR

Graphical network of the top 20 diseases related to Laryngeal Squamous Cell Carcinoma:



Diseases related to Laryngeal Squamous Cell Carcinoma

Symptoms & Phenotypes for Laryngeal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.62 AURKA EGFR
2 Decreased viability GR00221-A-1 9.62 AURKA CDH1 CDKN2A EGFR NME1
3 Decreased viability GR00221-A-2 9.62 AURKA NME1
4 Decreased viability GR00221-A-3 9.62 CDKN2A
5 Decreased viability GR00221-A-4 9.62 AURKA CDKN2A EGFR
6 Decreased viability GR00231-A 9.62 AURKA
7 Decreased viability GR00301-A 9.62 CDH1
8 Decreased viability GR00402-S-2 9.62 AURKA CDH1 CDKN2A EGFR NME1

MGI Mouse Phenotypes related to Laryngeal Squamous Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 AURKA CCND1 CDH1 CDKN2A EGFR NME1

Drugs & Therapeutics for Laryngeal Squamous Cell Carcinoma

Drugs for Laryngeal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
2
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
3
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
4
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
5
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
6
Trioxsalen Approved Phase 2 3902-71-4 5585
7
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
8
leucovorin Approved Phase 2 58-05-9 143 6006
9 Antineoplastic Agents, Phytogenic Phase 2
10 Albumin-Bound Paclitaxel Phase 2
11 Arginyl-glycyl-aspartic acid Phase 2
12 Antibodies Phase 1, Phase 2
13 Antineoplastic Agents, Immunological Phase 1, Phase 2
14 Immunoglobulins Phase 1, Phase 2
15 Tubulin Modulators Phase 2
16 Antimitotic Agents Phase 2
17 Dihematoporphyrin Ether Phase 2
18 Hematoporphyrin Derivative Phase 2
19 Dermatologic Agents Phase 2
20 Photosensitizing Agents Phase 2
21 Ether Phase 2
22 Astragalus Phase 2
23
Serine Approved, Nutraceutical 56-45-1 5951
24 Cola
25 Serpins
26
protease inhibitors
27 Serine Proteinase Inhibitors
28 HIV Protease Inhibitors
29 Squamous cell carcinoma-related antigen
30
Diadenosine tetraphosphate 5542-28-9 21706
31 Platelet Aggregation Inhibitors

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 A Prospective Phase II Study of Involved Field Elective Volume De-Intensification for Oropharyngeal and Laryngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiation Therapy Completed NCT03067610 Phase 2 chemotherapy
2 A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
3 A Phase I/II Study of Chemo Radiation Plus the Anti-Programmed Death-1 (Anti-PD-1) Antibody, Pembrolizumab (MK-3475) for Locally Advanced Laryngeal Squamous Cell Carcinoma Recruiting NCT02759575 Phase 1, Phase 2 Pembrolizumab;Cisplatin
4 Immuno-Chemotherapy as Single Treatment Modality for Larynx Preservation (ICoLP) Recruiting NCT04030455 Phase 2 Carboplatin;Cisplatin;Docetaxel
5 A Phase II Randomized Sham-Controlled Trial With Allocation Concealment and Blinded Patients and Assessors, Investigating Hyperbaric Oxygen as a Radiation Sensitizer for Locally Advanced Squamous Cell Carcinoma of the Oropharynx and Larynx Not yet recruiting NCT03843671 Phase 2 Hyperbaric oxygen
6 Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II Terminated NCT02068157 Phase 2 Photodynamic Therapy;Porfimer Sodium
7 A Phase II Double-blind and Randomized Trial Comparing Concurrent Chemoradiotherapy Plus PG2 Injection Versus Concurrent Chemoradiotherapy Plus Placebo in Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Terminated NCT01720563 Phase 2 Astragalus polysaccharides 500 mg;Placebo
8 Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
9 Quality of Life After Laser Cordectomy in Early Glottic Cancer Unknown status NCT02184403
10 Validation of a Screening Tool in Geriatric Oncology Completed NCT00963911
11 Hyperfractionation and Accelerated Fractionation in Comparison With Conventional Fractionation in Definitive Radiotherapy of Squamous Cell Carcinoma of Larynx, Oropharynx and Hypopharynx Completed NCT00291434
12 Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions Completed NCT02217358
13 Development and Validation of Nomograms to Precisely Predict Conditional Risk of Recurrence for Patients With Laryngeal Cancer: a Single-institutional Study Recruiting NCT03595410
14 Development and Validation of Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer: a Single-institutional Study Recruiting NCT03747783
15 Isolation, Quantification and Kinetics of Salivary Ap4A, SCCA and TROP2 in Patients With Oral Cancer and Potentially Malignant Oral Disorders Active, not recruiting NCT03529604

Search NIH Clinical Center for Laryngeal Squamous Cell Carcinoma

Genetic Tests for Laryngeal Squamous Cell Carcinoma

Anatomical Context for Laryngeal Squamous Cell Carcinoma

MalaCards organs/tissues related to Laryngeal Squamous Cell Carcinoma:

41
Lymph Node, Thyroid, Endothelial, Neutrophil, T Cells, Skin, Breast

Publications for Laryngeal Squamous Cell Carcinoma

Articles related to Laryngeal Squamous Cell Carcinoma:

(show top 50) (show all 1866)
# Title Authors PMID Year
1
GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population. 9 38
19922706 2010
2
Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. 9 38
19741544 2010
3
EGFR immunoexpression and peripheral blood cytokine secretion as potential biomarkers of tumor behavior in laryngeal squamous cell carcinoma. 9 38
19789511 2009
4
Protein expression of epidermal growth factor receptor in laryngeal squamous cell carcinoma index tumors correlates with diagnosis of second primary tumors of the upper aero-digestive tract. 9 38
19669840 2009
5
Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter. 9 38
19375219 2009
6
[Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]. 9 38
19813623 2009
7
[The expressions and correlation of AQP1 and VEGF in laryngeal squamous cell carcinoma]. 9 38
19670620 2009
8
[The expression of Galectin-3 and VEGF in laryngeal squamous cell carcinoma]. 9 38
19452726 2009
9
Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma. 9 38
19148533 2009
10
p53, epidermal growth factor receptor and proliferating cell nuclear antigen in laryngeal squamous cell carcinoma are not predictive markers for the effect of adjuvant radiotherapy. 9 38
18607952 2009
11
Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck. 9 38
19183379 2009
12
Cell growth inhibition and down-regulation of survivin by silibinin in a laryngeal squamous cell carcinoma cell line. 9 38
18998509 2008
13
[hTERT promoter enhances the radiosensitivity to gene-radiation therapy of human laryngeal carcinoma transplanted in nude mice]. 9 38
19173799 2008
14
[Expression of angiopoietin-1,2 and its relationship with angiogenesis in laryngeal squamous cell carcinoma]. 9 38
19086654 2008
15
Prognostic value of cell-cycle regulators and cellular biomarkers in laryngeal squamous cell carcinoma. 9 38
18602381 2008
16
[Effect of CDK2 on proliferation in laryngeal squamous cell carcinoma]. 9 38
19166026 2008
17
[Study of the lymph node micrometastasis in patients with supraglottic carcinoma]. 9 38
19166031 2008
18
[Detection of Skp2 mRNA gene expression using fluorogenic probe quantitative RT-PCR method in laryngeal squamous cell carcinoma]. 9 38
18800682 2008
19
Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma. 9 38
18509272 2008
20
Short hairpin ribonucleic acid targeting the telomerase catalytic unit of messenger ribonucleic acid significantly limits the growth of laryngeal squamous cell carcinoma in nude mice. 9 38
17592663 2008
21
Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis. 9 38
18357366 2008
22
[Expression of cyclin G1 in laryngeal squamous cell carcinoma and its clinicopathologic significance]. 9 38
18788592 2008
23
[Expression of Survivin, Caspase-3 and p53 in surgical margin of laryngeal squamous cell carcinoma and their relationship]. 9 38
18476631 2008
24
Possible prognostic role of p53 expression in laryngeal squamous cell carcinoma of non-smokers, non-alcoholic patients. 9 38
18607961 2008
25
Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. 9 38
18787961 2008
26
Expression of PTEN protein in patients with laryngeal squamous cell carcinoma. 9 38
17475427 2007
27
[Effects of HPV 16-E6/E7 oncogene on expression of vascular endothelial growth factor and matrix metalloproteinase 9 in human laryngeal squamous cell carcinoma cell line]. 9 38
18307884 2007
28
Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. 9 38
17974987 2007
29
Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients' prognosis. 9 38
17712678 2007
30
[Expression and clinical significance of Endostatin, vascular endothelial growth factor and fibroblast growth factor basic-2 in laryngeal carcinoma]. 9 38
18051571 2007
31
[Expression and role of survivin in laryngeal squamous cell carcinoma and laryngeal papilloma in adults]. 9 38
17634026 2007
32
[Clinical significance and expression of FLIP and PTEN protein in laryngeal squamous cell carcinoma]. 9 38
17441421 2007
33
Combined p14ARF and antisense EGFR potentiate the efficacy of adenovirus-mediated gene therapy in laryngeal squamous cell carcinoma (LSCC). 9 38
17328665 2007
34
The role of host immune response and apoptosis in patients with laryngeal squamous cell carcinoma. 9 38
17264532 2007
35
[Expression and clinical significance of matrix metalloproteinase-2 in laryngeal squamous cell carcinoma]. 9 38
17357514 2006
36
5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. 9 38
17207318 2006
37
[Expression of telomerase reverse transcriptase and its relationship with expression of c-myc in laryngeal squamous cell carcinomas]. 9 38
17219990 2006
38
Relation of glutathione S-transferase genotypes (GSTM1 and GSTT1) to laryngeal squamous cell carcinoma risk. 9 38
16938565 2006
39
Expression of the apoptosis inhibitor protein Survivin in primary laryngeal carcinoma and cervical lymph node metastasis. 9 38
17094406 2006
40
Immunohistochemical estimation of cell cycle phase in laryngeal neoplasia. 9 38
16832409 2006
41
[The investigation of STK15 gene amplification and overexpression in laryngeal squamous cell carcinoma]. 9 38
16767676 2006
42
[Construction of recombinant adenovirus vector carrying cell cycle controlling gene-p14ARF]. 9 38
16845966 2006
43
[The relationship between hypermethylation of the PTEN promoter and laryngeal squamous cell carcinoma]. 9 38
16739377 2006
44
[The clinical significance of the expression of p63 gene in laryngeal squamous cell carcinoma]. 9 38
16646404 2006
45
Promoter hypermethylation of DNA repair gene MGMT in laryngeal squamous cell carcinoma. 9 38
16711019 2006
46
[Inhibitory effect of silencing hTERT gene by short hairpin RNA on growth of human laryngeal squamous cell carcinoma xenograft in nude mice]. 9 38
16405742 2006
47
[The correlation of vascular endothelial growth factor with angiogenesis and p53 gene in laryngeal squamous cell carcinoma]. 9 38
16763427 2006
48
Expression of vascular endothelial growth factor and cyclooxygenase-2 in laryngeal squamous cell carcinoma and its significance. 9 38
16711020 2006
49
TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. 9 38
15965904 2006
50
Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. 9 38
16265652 2006

Variations for Laryngeal Squamous Cell Carcinoma

Cosmic variations for Laryngeal Squamous Cell Carcinoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM45571 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.593A>G p.E198G 17:7674938-7674938 0

Expression for Laryngeal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Laryngeal Squamous Cell Carcinoma.

Pathways for Laryngeal Squamous Cell Carcinoma

Pathways related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.72 TP53 EGFR CDKN2A CDH1 CCND1
2 12.57 TP53 TERT EGFR CDKN2A CDH1 CCND1
3
Show member pathways
12.5 TP53 EGFR CDKN2A CDH1 CCND1
4
Show member pathways
12.4 TP53 TERT EGFR CDKN2A CDH1 CCND1
5 12.36 TP53 CDKN2A CCND1 AURKA
6 12.32 TP53 MIR21 EGFR CDKN2A CCND1
7 12.2 TP53 TERT CDKN2A CCND1
8 12.18 TP53 CDKN2A CDH1 CCND1
9 12.09 TP53 MIR21 EGFR CCND1
10 11.98 TP53 EGFR CDH1 CCND1
11 11.74 TP53 EGFR CDH1 CCND1 AURKA
12 11.67 TP53 EGFR CDKN2A CCND1
13 11.63 TP53 TERT NME1
14 11.61 TERT CDH1 CCND1
15 11.49 TERT EGFR CCND1
16 11.1 NME1 CDH1 CCND1
17 10.96 TP53 EGFR CDKN2A CCND1
18 10.88 TP53 EGFR CDKN2A CDH1 CCND1
19 10.65 TP53 HOTAIR

GO Terms for Laryngeal Squamous Cell Carcinoma

Biological processes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 TP53 TERT MIR21 EGFR AURKA
2 regulation of protein stability GO:0031647 9.61 TERT CDKN2A AURKA
3 cellular response to drug GO:0035690 9.54 TP53 NME1 EGFR
4 liver regeneration GO:0097421 9.43 EGFR CCND1 AURKA
5 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.4 TP53 EGFR
6 negative regulation of gene expression GO:0010629 9.35 TERT NME1 MIR21 HOXA11-AS CDKN2B-AS1
7 mitotic G1 DNA damage checkpoint GO:0031571 9.32 TP53 CCND1
8 response to UV-A GO:0070141 9.16 EGFR CCND1
9 replicative senescence GO:0090399 8.8 TP53 TERT CDKN2A

Molecular functions related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.02 TP53 EGFR CDKN2A CCND1 AURKA

Sources for Laryngeal Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....